Veriskin is a medical device company dedicated to facilitating and improving the accuracy of skin cancer screening.
Meet Veriskin, Inc.
Why is your company the best option to solve the problem you're solving?
Despite multiple attempts no device or technology has succeeded in the skin cancer diagnostics market so far. Veriskin believes that a high diagnostic accuracy (high sensitivity and specificity) and ease-of-use are prerequisites for widespread clinical adoption.
What nuggets of info make you interesting? Why do people care about what you're doing?
Skin cancer is the most common cancer in the US with >5M cases annually i.e. more people are diagnosed with skin cancer each year in the U.S. than all other cancers combined. It is hard to find someone who does not have (or had) that suspect skin blemish and was not worrying whether it could be a deadly melanoma cancer. With aging population skin cancer incidence rates are increasing 3 % to 7 % a year.
What else do you want us to know?
Veriskin has been supported by the National Cancer Institute of the NIH with two grant awards totaling at $3.9M.
BEHIND THE COMPANY
Founder/CEO: Mirianas Chachisvilis
What is your company's secret sauce?
Veriskin has developed patented technology that is unique and orthogonal to the approaches that have been tried before enabling us to achieve unparalleled diagnostic accuracy.